Nature Medicine (journal)

March 7, 2024

Blood mutations increase risk for acute kidney injury: study

A U.S.-Canadian research collaboration led by Vanderbilt University Medical Center has identified common, age-associated changes in the blood as a risk factor for acute kidney injury, which occurs in more than 1 in 5 hospitalized adults worldwide.

By Bill Snyder
February 19, 2024

VUMC part of major step to achieving precision medicine

An analysis of genomic data from nearly 250,000 participants in the National Institutes of Health’s All of Us Research Program has identified more than 275 million previously unreported genetic variations, nearly 4 million of which have potential health consequences.

By Bill Snyder
October 17, 2023

Tirzepatide trial shows additional 21.1% weight loss following intensive lifestyle intervention

A Vanderbilt clinical trial evaluating the injectable prescription medication tirzepatide, showed an additional 21.1% weight loss after intensive lifestyle intervention in adults with obesity or who were overweight with weight-related comorbidities, excluding Type 2 diabetes.

By Jill Clendening
Sharon Kantanie, center, participated in the study of a drug that reduced soft-tissue flare-ups and the prevented new areas of abnormal bone formation. With her are, from left, Emily Shardelow, clinical/translational research coordinator; Sharon’s parents, Mary and Stan Kantanie; Margo Black, MSN, manager of research projects for Metabolic Bone Disorders; and Kathryn Dahir, MD, professor of Endocrinology and Diabetes. (photo by Erin O. Smith)
September 28, 2023

Drug trial shows reduced abnormal bone formation in those with fibrodysplasia ossificans progressiva

A Vanderbilt clinical trial evaluating the investigational drug garetosmab has shown that it reduced soft-tissue flare-ups significantly and prevented new areas of abnormal bone formation in patients with fibrodysplasia ossificans progressiva.

By Jill Clendening
July 7, 2023

Rett syndrome drug studied at Vanderbilt approved for patients

The first drug to treat the symptoms of Rett syndrome was recently approved, following a Nature Medicine study publishing results from the pivotal phase 3 LAVENDER study led by investigators from Vanderbilt University Medical Center to evaluate efficacy and safety of trofinetide.

By Craig Boerner
The study found that increasing number of steps taken each day can steps taken daily can reduce the risk of several common, chronic diseases. (istock image)
October 10, 2022

Counting steps can reduce disease risk: study

A Vanderbilt study found that using a wearable activity tracker to count and increase the number and intensity of steps taken daily can reduce the risk of several common, chronic diseases.

By Bill Snyder
March 7, 2022

Study finds World Trade Center responders at higher risk for blood cancer-associated mutations

A study by Vanderbilt and New York City researchers found that 9/11 first responders to the World Trade Center have increased levels of mutations that escalate their risk for blood cancers or cardiovascular disease
By Tom Wilemon
December 16, 2021

Two VUMC papers named among genomic medicine’s top 10

Vanderbilt researchers wrote two of the “top 10” papers representing key advances in genomic medicine published between September 2020 and August 2021.
By Bill Snyder
June 3, 2021

Predictive model identifies patients for genetic testing

Patients who, perhaps unbeknownst to their health care providers, are in need of genetic testing for rare undiagnosed diseases can be identified en masse based on routine information in electronic health records (EHRs), a research team reported June 3 in the journal Nature Medicine.
By Paul Govern
March 4, 2021

Monoclonal antibody “cocktail” blocks COVID-19 variants: study

A monoclonal antibody “cocktail” developed at Vanderbilt University Medical Center to neutralize the COVID-19 virus is effective against all known strains, or variants, of the virus, according to a report published today in the journal Nature Medicine.
By Bill Snyder
July 15, 2020

Antibody research at Vanderbilt University Medical Center shows promise in fight against COVID-19

Based on positive results in preclinical studies reported today, potently neutralizing antibodies identified by researchers at Vanderbilt University Medical Center are showing promise as a potential therapy for preventing and treating COVID-19.
By Bill Snyder
July 13, 2020

Human lungs rejected for transplant recovered using novel technique

A multidisciplinary team from Vanderbilt University Medical Center and Columbia University has demonstrated that injured human donor lungs declined for transplant can be recovered by cross-circulation between the human lung and a xenogeneic host.
By Matt Batcheldor
May 27, 2020

Target trials support drug safety in pregnant patients

Out of concern for fetal safety, pregnant people have typically been excluded from drug trials. And when human health is on the line, drug studies assessing fetal safety in animal models may be viewed as far from definitive.
By Paul Govern
1 2